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Hyperphosphorylation amplifies UPF1 activity to
resolve stalls in nonsense-mediated mRNA decay
Se´bastien Durand1, Tobias M. Franks1 & Jens Lykke-Andersen1
Many gene expression factors contain repetitive phosphorylation sites for single kinases,
but the functional significance is poorly understood. Here we present evidence for
hyperphosphorylation as a mechanism allowing UPF1, the central factor in nonsense-
mediated decay (NMD), to increasingly attract downstream machinery with time of residence
on target mRNAs. Indeed, slowing NMD by inhibiting late-acting factors triggers UPF1
hyperphosphorylation, which in turn enhances affinity for factors linking UPF1 to decay
machinery. Mutational analyses reveal multiple phosphorylation sites contributing to different
extents to UPF1 activity with no single site being essential. Moreover, the ability of UPF1 to
undergo hyperphosphorylation becomes increasingly important for NMD when downstream
factors are depleted. This hyperphosphorylation-dependent feedback mechanism may
serve as a molecular clock ensuring timely degradation of target mRNAs while preventing
degradation of non-targets, which, given the prevalence of repetitive phosphorylation among
central gene regulatory factors, may represent an important general principle in gene
expression.
DOI: 10.1038/ncomms12434 OPEN
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T
he correct control of gene expression requires coordination
of multiple transcriptional and post-transcriptional pro-
cesses. Thousands of genes or gene products use a shared
pool of core gene expression machineries to carry out each step of
gene expression. This is orchestrated by regulatory DNA- and
RNA-binding factors, many of which target subsets of genes or
gene products for regulation of specific steps in gene expression.
However, the mechanisms by which gene-specific factors ensure
timely regulation of their target genes or gene products in the face
of changing demands for the core gene expression machineries is
poorly understood.
RNA quality-control pathways maintain fidelity in gene
expression by targeting faulty RNAs for decay1. Nonsense-
mediated decay (NMD) is a quality-control pathway that
monitors the integrity of gene expression by degrading
messenger RNAs (mRNAs) that have acquired premature
termination codons (PTCs), for example, through mutations, or
errors in transcription or mRNA processing2–6. Given the
potential for mRNAs with PTCs to cause accumulation of
detrimental truncated protein products, the ability of NMD to
degrade these mRNAs likely needs to be continuously sustained
to avoid deleterious consequences, no matter the current
availability of RNA decay machinery. Moreover, a critical
aspect of NMD is that non-target mRNAs must remain
immune to the pathway.
The detection of mRNAs with PTCs occurs during translation
termination and is directed by the superfamily 1 RNA helicase
UPF1 and co-factors7–11. In metazoans, subsequent to PTC
recognition, UPF1 is phosphorylated by the phosphatidylinositol-
kinase related kinase (PIKK) SMG1 at [S/T]Q motifs12,13. This
activates downstream steps in the pathway carried out by the
endonuclease SMG6 as well as the adaptor proteins SMG5, SMG7
and PNRC2, which connect UPF1 to the general decapping,
deadenylation and exonucleolytic decay machineries14–23. While
UPF1 specifically targets NMD substrates for degradation, our
recent evidence suggests that UPF1 transiently associates with all
translated mRNAs, but a mechanism dependent on UPF1 ATPase
activity prevents the stable assembly of UPF1 with non-targets24.
Intriguingly, an evolutionary conserved property of UPF1 is its
ability to undergo hyperphosphorylation13,19,22,25–28, a feature
that is shared with many prominent factors in gene expression,
including RNA polymerase II and SR proteins for which the
importance of phosphorylation in gene expression is well
described29–31. Metazoan UPF1 proteins contain a multitude of
[S/T]Q motifs in the N- and C-terminal regions, the majority of
which are evolutionarily conserved (for example, 19 in humans;
Supplementary Fig. 1a). Specific [S/T]Q motifs in human UPF1
have been characterized as phosphorylation-dependent binding
sites for downstream factors in the NMD pathway10,17,32,33, but
the functional role of other [S/T]Q motifs and the significance
of UPF1 undergoing hyperphosphorylation has remained
uncharacterized.
Previous studies conducted to understand principles of
UPF1 phosphorylation observed that phosphorylation of
UPF1 increases on depletion of SMG5, SMG6 or SMG7 in
Caenorhabditis elegans and human cells10,22,25,28. Those
observations, together with an observed association of
phosphatase 2A with SMG5-7 (refs 22,25,34), led to the
conclusion that SMG5-7 promote UPF1 dephosphorylation.
Here given the more recently demonstrated role of SMG5-7 in
linking UPF1 to mRNA decay14,16–19,21,23, we considered the
alternative but not necessarily mutually exclusive possibility that
the increase in UPF1 phosphorylation on SMG5-7-depletion is
caused by continuous phosphorylation of UPF1 as a consequence
of a stall in the NMD pathway. Indeed, we find that multiple
interventions that impair the NMD pathway downstream of
UPF1 mRNA assembly, including mutation of the UPF1 ATPase
and depletion of NMD-specific and general mRNA decay factors,
all result in increased UPF1 phosphorylation. Moreover, UPF1
undergoes increased phosphorylation upon stimulation of the
AU-rich element (ARE)-mediated mRNA decay pathway, which
uses shared mRNA decay machinery. Mutational analyses
demonstrate that no single phosphorylation site in UPF1 is
essential for NMD, but multiple phosphorylation sites contribute
to NMD efficiency with some sites being more important than
others. Depletion of downstream NMD factors, SMG5 or
SMG7, causes increased dependence of NMD on UPF1
hyperphosphorylation. Taken together, our observations suggest
that UPF1 hyperphosphorylation serves as a feedback mechanism
to ensure efficient degradation of mRNAs that stably assemble
with UPF1. This could serve to ensure that NMD non-targets
evade NMD despite their transient association with UPF1
(ref. 24), and to resolve stalls in the NMD pathway ensuring
that mRNAs targeted for NMD are efficiently degraded even
under conditions where downstream NMD-specific or general
mRNA decay factors are limiting.
Results
Inhibiting late NMD steps increases UPF1 phosphorylation.
To determine whether increased phosphorylation of UPF1 is a
general response to stalls in downstream steps of the NMD
pathway, we inhibited various steps of the NMD pathway and
performed anti-UPF1 immunoprecipitation (IP) followed by
western blotting using a general phospho-[S/T]Q antibody
to monitor relative levels of [S/T]Q-phosphorylated UPF1.
Consistent with the previous reports10,22,25,28,35, depletion of
NMD factors SMG7, SMG6 or SMG5 resulted in increased UPF1
phosphorylation (Fig. 1a; depletion efficiencies shown in
Supplementary Fig. 1b) and mutant UPF1 proteins with
deficiencies in ATP hydrolysis (DE636/637AA) or ATP binding
(K498A, G495R and G497E), known to become trapped on
mRNAs and stalling NMD24,36,37, all accumulate with higher
levels of phosphorylation than wild-type UPF1 (Fig. 1b). In
addition, depletion of PNRC2 resulted in increased UPF1
phosphorylation (Fig. 1a, depletion efficiencies shown in
Supplementary Fig. 1b,e). We also tested UPF1 phosphorylation
levels following interventions that impair general mRNA decay
factors. As seen in Fig. 1c,d, depletion of the 50-to-30 exonuclease
XRN1 and the decapping activator HEDLS, as well as exogenous
expression of a dominant negative form of the decapping enzyme
DCP2 (DCP2-E148Q) augmented UPF1 phosphorylation
(Fig 1c,d; see Supplementary Fig. 1c,d for depletion and
expression levels), whereas exogenous expression of a dominant
negative form of the deadenylase CAF1B (CAF1B-DDAA)
showed inconsistent effects on UPF1 phosphorylation (Fig. 1d).
We conclude that interventions that impair steps in the NMD
pathway downstream of UPF1 assembly with mRNA substrates,
including manipulations of NMD-specific factors as well as
general mRNA decay factors, lead to increased UPF1
phosphorylation. We note that a correlation appears to exist
between the severity of the NMD defect and the extent of UPF1
phosphorylation, as those of the tested conditions known to most
severely inhibit NMD—that is, depletion of SMG6 and mutations
of the UPF1 ATPase10,16,35,36,38,39—also cause the largest
increase in phosphorylation (Fig. 1a–d).
UPF1 hyperphosphorylation on inhibition of late NMD steps.
The experiments in Fig. 1 monitored relative levels of UPF1
[S/T]Q phosphorylation, but were not designed to discriminate
between an increase in the overall pool of phosphorylated UPF1
versus an increase in the number of phosphorylated residues
within individual UPF1 molecules. Moreover, given that the
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12434
2 NATURE COMMUNICATIONS | 7:12434 |DOI: 10.1038/ncomms12434 | www.nature.com/naturecommunications
phospho-[S/T]Q antibody could react with some phosphorylation
sites more than others, there may not be a linear relationship
between the extent of UPF1 phosphorylation and the
signal observed in Fig. 1. To address whether UPF1 accumulates
in a hyperphosphorylated form upon inhibition of downstream
steps in NMD, we performed two-dimensional (2D) gel
electrophoresis, as previously used to monitor UPF1 hyper-
phosphorylation26,40. As seen in Fig. 2a, depletion of SMG6 or
XRN1 resulted in a heterogeneous shift of UPF1 towards lower
isoelectric points, as compared with the control condition (left
panels, pixel density quantified below, and depletion efficiencies
shown in Supplementary Fig. 2). This shift is particularly striking
with SMG6 depletion, which also showed the greatest effect in
overall phosphorylation levels as monitored in the IP–western
blots (Fig. 1a). While the 2D gels do not reveal the exact number
of phosphorylations or the extent of phosphorylation at
individual sites, the observed change in UPF1 isoelectric points
is due to UPF1 hyperphosphorylation as treatment with l
phosphatase collapsed the signal and generated UPF1 profiles for
SMG6 and XRN1 siRNA-treated cells that were indistinguishable
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Figure 2 | UPF1 is hyperphosphorylated upon SMG6 and XRN1 depletion and upon inhibition of ATPase activity. (a) Two-dimensional gel
electrophoresis assays performed on extracts from HeLa tet-off cells transfected with siRNAs targeting Firefly Luciferase (siLUC), SMG6 (siSMG6) or
XRN1 (siXRN1) and subjected to western blotting with anti-UPF1 antibody. Prior to electrophoresis, cell lysates were treated (þ l phosphatase; right panel)
or not (left panel) with lambda protein phosphatase. Graphs indicate signal intensity along the blots normalized to the total signal intensity.
(b) Two-dimensional gel electrophoresis assays performed on extracts from HeLa tet-off cells transfected with plasmids coding for myc-tagged wild-type
UPF1 (Upf1-WT) or UPF1 DE636/637AA. The graph indicates signal intensity along the blots normalized to the total signal intensity.
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Figure 1 | Inhibition of UPF1 ATPase and disruption of decay activities increase UPF1 phosphorylation. (a) Western blots monitoring phosphorylation
levels of endogenous UPF1 in HeLa tet-off cells transfected with indicated siRNAs followed by IP for UPF1 and anti-phospho-[S/T]Q (P-UPF1) and anti-UPF1
(UPF1) western blotting. Indicated phosphorylation levels were calculated from at least three independent experiments by dividing the P-UPF1 signal with
that from anti-UPF1 (UPF1) and are shown normalized to control (LUC) conditions±s.e.m. P values are indicated below panels and are relative to control
conditions (paired two-tailed Student’s t-test). (b) Same as in a in HeLa tet-off cells transfected with myc-tagged UPF1 wild-type (‘WT’), ATP-hydrolysis
mutant (DE636/637AA) or ATP-binding mutants (K498A, G495R and G497E). Indicated phosphorylation levels were calculated as in a and are shown
normalized to control (‘WT’) conditions±s.e.m. (c) Same as in a in HeLa tet-off cells transfected with indicated siRNAs. UPF1 phosphorylation levels were
quantified as in a. (d) Same as in a in HeLa tet-off cells transfected with plasmids coding for myc-tagged UPF1 together with an empty vector (none) or
vectors expressing CAF1B DDAA or DCP2 E148Q. UPF1 phosphorylation levels were quantified as in a and are shown normalized to control (‘none’)
conditions±s.e.m.
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from that of control cells (Fig. 2a, right panels). Similarly, the
ATPase-deficient UPF1 DE636/637AA mutant protein showed a
shift towards lower isoelectric points as compared with wild-type
UPF1 (Fig. 2b). Collectively, our observations demonstrate that
disruption of steps in the NMD pathway downstream of UPF1
substrate binding induces UPF1 hyperphosphorylation and that
the extent of phosphorylation correlates with the severity of the
NMD defect.
Increase in phospho-UPF1 on ARE-mediated decay activation.
Given the observed hyperphosphorylation of UPF1 in response to
mRNA decay factor depletion, we predicted that UPF1 might
compensate with increased phosphorylation on over-activation of
an unrelated mRNA decay pathway that uses RNA decay factors
shared with NMD. A well-studied example of a highly induced
mRNA decay pathway occurs during an inflammatory response,
when a rapid induction in cytokine and chemokine mRNAs is
subsequently quenched by activation of the ARE-mediated
mRNA decay pathway41. This pathway employs several mRNA
decay factors also used by NMD42–44. As seen in Fig. 3a,b, a
transient induction in UPF1 phosphorylation, peaking at 2.5 to
3 times the signal observed for unstimulated cells, occurred on
treatment of RAW 264.7 macrophages with lipopolysaccharides
(LPS, mimicking bacterial infection; Fig. 3a) and of NIH 3T3
fibroblasts with serum (mimicking injury; Fig. 3b, upper panel).
This occurred without an increase in levels of UPF1 (Fig. 3a,b)
or of the UPF1 kinase SMG1 (Supplementary Figs 3a,b).
The timing of UPF1 phosphorylation induction correlates with
the previously described timing of ARE-mediated mRNA decay
activation in these cell lines45,46. Importantly, the transient
increase in UPF1 phosphorylation occurs in response to
activation of the ARE-mRNA decay pathway as depletion
of the responsible mRNA decay activators in NIH 3T3 cells,
ZFP36, ZFP36L1 and ZFP36L2, abolished the peak in UPF1
phosphorylation (Fig. 3b), despite the ZFP36/L1/L2-depleted cells
responding to serum induction similarly to the control cells as
monitored by cFOS expression (Supplementary Fig. 3b). With the
caveat that indirect effects on SMG1 activity cannot be ruled out,
the simplest interpretation of these observations is that increased
UPF1 phosphorylation occurs in response to activation of an
mRNA decay pathway that competes for shared mRNA decay
machinery.
Multiple UPF1 [S/T]Q motifs contribute to NMD efficiency.
To directly test the contribution of the multiple UPF1 [S/T]Q
motifs to UPF1 activity, we constructed plasmids coding for
siRNA-resistant versions of UPF1 containing combinations of
[S/T]Q to AQ substitutions spanning 12 potential or confirmed
phosphorylation sites (Fig. 4a), including sites at positions 28,
1,078, 1,096 and 1,116 that were previously observed to promote
association with SMG5-7 proteins10,13,17,22,33. These mutations
are unlikely to affect UPF1 structurally, as the N- and C-terminal
regions of UPF1 containing the [S/T]Q motifs are predicted
to be unstructured (Supplementary Fig. 4a), and all mutant
proteins maintained an unimpaired interaction with UPF2
(Supplementary Fig. 4b). To test the effect of the [S/T]Q to AQ
substitutions on UPF1 function, we monitored the ability of
UPF1 mutants to complement siRNA-depleted endogenous UPF1
in the degradation of b-globin mRNA containing a PTC at
position 39 (b39).
Consistent with phosphorylation at S1096 (here for simplicity
labelled position 18; Fig. 4a) playing an important role in NMD,
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Figure 3 | Transient increase in UPF1 phosphorylation upon activation of ARE-mediated decay. (a) Western blots showing endogenous UPF1
phosphorylation levels in RAW 264.7 cells treated with LPS and monitored as in Fig. 1a. Numbers refer to hours after LPS addition. Graph showing UPF1
phosphorylation levels quantified as in Fig. 1 is shown below. Indicated values are normalized to the zero time point±s.e.m. from three independent
experiments. P values are relative to time zero and were calculated using paired two-tailed Student’s t-test. (b) Western blots showing UPF1
phosphorylation levels in NIH 3T3 cells transfected with siRNAs targeting either Firefly Luciferase (LUC) or ZFP36, ZFP36L1 and ZFP36L2 (ZFP36/L1/L2).
Numbers above panels refer to time after serum induction; lower panel shows uninduced cells. Graph showing UPF1 phosphorylation levels measured from
three independent experiments as in a is shown below. P value is comparing siLUC to siZFP36/L1/L2 conditions at 1 h after serum induction using the
paired two-tailed Student’s t-test.
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Figure 4 | Multiple UPF1 [S/T]Q motifs contribute to NMD. (a) Schematic representation of human UPF1 protein showing the amino acids mutated in
this study (black); the position of the helicase domain and the cysteine/histidine-rich domain (CH) of UPF1 are indicated (not to scale). Numbers following
amino-acid symbols correspond to the position in the UPF1 primary sequence (GenBank #NP_002902). Asterisk indicates confirmed phosphorylated sites.
[S/T]Q motifs not investigated in this work are shown in grey. (b) Northern blots showing the decay of b39 mRNA in HeLa Tet-Off cells depleted for
endogenous UPF1 and expressing myc-tagged variants of UPF1 as indicated. Numbers above panels refer to minutes after tetracycline-mediated
transcriptional shutoff of b39 mRNA (chase). b39 mRNA half-lives (t1/2) were calculated after normalization of levels of b39 mRNA to levels of
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on the right refer to RNA lengths in nucleotides (nts) excluding polyA-tails. (c) Graph showing half-lives calculated from experiments presented in b. Lower
and upper dotted lines represent half-life values for wild-type UPF1 (Upf1-wt) and no add-back (None) conditions respectively. Error bars represent s.e.m.
from three independent experiments. P values were calculated relative to Upf1-wt conditions using the paired two-tailed Student’s t-test; *Po0.05 and
**Po0.01.
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alanine substitutions at positions 17 and 18 caused an increase in
the half-life of the b39 mRNA (UPF1 [S/T]17,18A) as compared
with that observed with wild-type UPF1 (UPF1-wt; Fig. 4b;
quantified in Fig. 4c). Nevertheless, this mutant UPF1 protein was
only partially impaired in NMD, supporting degradation of b39
mRNA at a significantly faster rate than that observed in the
absence of UPF1 add-back (None), or in the presence of UPF1
C126S, a mutant UPF1 protein that fails to interact with UPF2
(refs 10,47). No defect in NMD activity was observed for the
UPF1 [S/T]1,2A, [S/T]15,16A or [S/T]7,8,19A mutants, which
was surprising because phosphorylation at residues T28 (here
called position 2), S1078 (position 16) and S1116 (position 19)
have previously been shown to support interaction with SMG6
(T28), SMG7 (S1078) and SMG5 (S1116)10,17,22,33. Strikingly,
combining alanine substitutions that on their own had little or no
effect on UPF1 activity, resulted in decreased activity of UPF1 as
observed by the increase in b39 mRNA half-lives as [S/T]Q to
AQ substitutions were combined, culminating in completely
inactivated UPF1 (Fig. 4b,c; compare mutations left to right)
despite equal expression of all mutant proteins (Supplementary
Fig. 4c). We conclude that none of the 12 tested [S/T]Q motifs are
essential for UPF1 function, but multiple [S/T]Q motifs
contribute to UPF1 activity with some (such as S1096, and
possibly T28, S1078 and S1116) appearing to contribute more
than others.
UPF1 hyperphosphorylation enhances association with SMG5-7.
What could be the significance of multiple phosphorylation
sites contributing to UPF1 function (Fig. 4) and UPF1 under-
going hyperphosphorylation when downstream factors are
limiting (Figs 1 and 2)? Given evidence from others that UPF1 is
a target of SMG1 only when assembled with mRNA10,22,48,
we hypothesized that UPF1 hyperphosphorylation occurs as a
consequence of UPF1 stalling on mRNA targets, which in turn
allows increased affinity of UPF1 for downstream factors to
enhance decay. If so, it is predicted that stalls in the NMD
pathway that result in increased UPF1 phosphorylation
should lead to increased association of UPF1 with downstream
factors in a phosphorylation-dependent manner. Indeed, UPF1
ATP binding and ATPase mutants, which accumulate in
hyperphosphorylated forms (Figs 1b and 2b), have previously
been observed to assemble more strongly with SMG5-7 than
wild-type UPF1 (refs 10,36). Similarly, as seen in the co-IP assays
in Fig. 5a, which were performed in the presence of RNase to
eliminate RNA-dependent interactions (Supplementary Fig. 5a),
depletion of SMG6 or XRN1 strongly increased complex
formation of UPF1 with SMG5 and SMG7 (compare lanes 2, 3
with 1). Moreover, complex formation of UPF1 with SMG6 was
enhanced on depletion of XRN1 (lane 3) and, to a lesser extent, of
SMG5/7 (lane 4). These observations show that manipulations
that impair the NMD pathway downstream of UPF1 mRNA
substrate binding result in increased RNA-independent
association of UPF1 with downstream SMG5-7 factors.
To test whether the observed increase in association of UPF1
with downstream factors is dependent on UPF1 phosphorylation,
we compared the extent of SMG5-7 complex formation for
UPF1 wild-type with two of the UPF1 [S/T]Q mutants: UPF1
[S/T]7,8,9,10,11,17,18,19A (labelled UPF1-8ST4A in Fig. 5b),
which is partially defective for NMD, and UPF1 [S/T]
1,2,7,8,9,10,11,15,16,17,18,19A (UPF1-12ST4A), which is fully
defective for NMD (Fig. 4). As seen in Fig. 5b, in contrast to wild-
type UPF1 (lanes 2, 6 and 10), the UPF1 [S/T]Q mutants fail to
acquire enhanced association with SMG5 and SMG7 on depletion
of SMG6 or XRN1 and instead maintain low level of SMG5 and
SMG7 association similar to that observed in the absence of
SMG6 or XRN1 depletion (compare lanes 7, 8, 11, 12 with 3, 4).
Similarly, as seen in Fig. 5c, wild-type and [S/T]Q mutant UPF1
can all be observed to associate with SMG6 (lanes 5-16), but only
wild-type UPF1 shows enhanced association with SMG6 on
depletion of XRN1 or SMG5/SMG7 (lanes 6–8). Thus, UPF1
appears to exhibit a basal level of affinity for SMG5-7 proteins
that is independent of hyperphosphorylation, consistent with
recent observations for SMG6 (refs 32,49), which is further
stimulated by phosphorylation. This was further supported by
in vitro pull-down assays, in which bacterially produced UPF1
was observed to associate with SMG5/7 and SMG6 in a manner
enhanced by phosphorylation with recombinant SQ-specific
ATM kinase (Fig. 5d). Collectively, the observations in Fig. 5
demonstrate UPF1 hyperphosphorylation as a mechanism for
enhancing the affinity of UPF1 for SMG5-7 proteins during a stall
in the degradation step of the NMD pathway.
UPF1 hyperphosphorylation importance upon SMG5/7 deple-
tion. If UPF1 hyperphosphorylation serves to enhance the affinity
of UPF1 for downstream factors on stalls in the NMD pathway,
then the ability of UPF1 to undergo hyperphosphorylation should
become increasingly important for NMD as the availability of
downstream factors is limited. Indeed, as seen in the mRNA
decay assays in Fig. 6a and Supplementary Fig. 6a, while low-level
depletion of SMG7 or SMG5 did not reduce the efficiency of
NMD in the presence of wild-type UPF1 (Fig. 6a, top left panel),
many of the UPF1 [S/T]Q mutants became impaired in their
NMD activity under these conditions (quantified in Fig. 6b,
compare white to grey bars) despite comparable SMG5/7 deple-
tion efficiencies (Supplementary Fig. 6b). This impairment in
NMD efficiency on SMG5 or SMG7 depletion became increas-
ingly pronounced as groups of [S/T]Q to AQ mutations were
combined (compare individual mutations in Fig. 6a and in
Supplementary Fig. 6a; P values, calculated using the paired
two-tailed Student’s t-test, are indicated in Fig. 6b). Thus, the
ability of UPF1 to undergo hyperphosphorylation becomes
increasingly important for NMD as downstream factors SMG5 or
SMG7 are rendered limiting, consistent with UPF1 hyperpho-
sphorylation playing an important role in rescuing slow kinetics
during the degradation phase of the NMD pathway. Collectively,
our findings suggest UPF1 hyperphosphorylation as an important
mechanism for the NMD pathway to sense and overcome lim-
itations in downstream factors including NMD-specific factors as
well as general mRNA decay machinery.
Discussion
Phosphorylation at specific sites within UPF1, the central factor
in NMD, was known to stimulate the association of UPF1 with
downstream SMG5-7 factors10,13,22,35,48, but why UPF1 contains
multiple phosphorylation sites, most of which are conserved over
evolution (Supplementary Fig. 1a) has been unclear. Here we
present evidence that no single phosphorylation site is essential
for UPF1 function, but multiple phosphorylation sites contribute
to UPF1 activity with individual sites contributing to different
extents, as evidenced by the cumulative effects on UPF1 activity
of mutations in phosphorylation sites (Fig. 4). Stalls in the NMD
pathway caused when NMD-specific or general mRNA decay
factors are rendered limiting result in hyperphosphorylation of
UPF1 (Figs 1 and 2) and in phosphorylation-dependent increased
affinity of UPF1 for downstream SMG5-7 factors (Fig. 5). The
ability of UPF1 to undergo hyperphosphorylation becomes
increasingly important for NMD when downstream SMG5 or
SMG7 NMD factors are limited (Fig. 6). Taken together,
these observations suggest a mechanism by which UPF1
hyperphosphorylation serves as a molecular clock to render
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12434
6 NATURE COMMUNICATIONS | 7:12434 |DOI: 10.1038/ncomms12434 | www.nature.com/naturecommunications
UPF1 increasingly proficient at activating the mRNA decay
machinery with time of residence on target mRNAs (Fig. 7), an
idea consistent with the specificity of the SMG1 kinase for
mRNA-associated UPF1 (refs 10,22,48). This hyperphosphoryla-
tion mechanism might play an important role in preventing
UPF1 from activating degradation of non-target mRNAs, which
we recently found transiently associate with UPF1 (ref. 24). It
might also ensure that the NMD pathway can rid the cell of
potentially deleterious aberrant mRNAs no matter current
demands on cellular mRNA decay machineries. Consistent with
the latter idea, manipulations that transiently activate the ARE-
mediated mRNA decay pathway in fibroblast and macrophage
cell lines triggered a transient spike in UPF1 phosphorylation,
which was dependent on the central ARE-mRNA decay factors
(Fig. 3).
How does a stall in mRNA degradation trigger UPF1
hyperphosphorylation? The simplest explanation is that UPF1
is phosphorylated by SMG1 specifically when assembled in an
mRNP complex, resulting in progressively increased phosphor-
ylation of UPF1 as the NMD-mRNP is awaiting degradation
(Fig. 7). This is consistent with previous studies suggesting
that UPF1 is a target of SMG1 only when assembled with
mRNA10,22,48. Indeed, previous studies found SMG1 locked in a
catalytic inactive state by SMG8 and SMG9 co-factors until the
SMG1/8/9 complex is recruited to NMD-targeted mRNPs50,51,
and UPF1 phosphorylation is dependent on complex formation
with UPF2 and translation release factors10.
How might increased UPF1 phosphorylation lead to increased
UPF1 activity? Our observations suggest that UPF1 hyperpho-
sphorylation results in increased affinity of UPF1 for downstream
SMG5-7 factors (Fig. 5), which in turn would increase the ability
of the resulting UPF1-cofactor complex to activate mRNA decay
(Fig. 7). Consistent with this, evidence has been presented for
phosphorylation of UPF1 at specific sites promoting association
with SMG5-7 proteins10,17,33. PNRC2, which has been shown to
link UPF1 with the DCP2 decapping complex, has also been
observed to associate preferentially with phosphorylated UPF1
(ref. 15). Our observations that none of the phosphorylation sites
currently known to interact with SMG5-7 proteins are essential
for NMD and that additional sites contribute to NMD efficiency
(Fig. 4), suggest that multiple phosphorylation sites can support
recruitment of downstream factors in the pathway. It is also a
possibility that increased phosphorylation of UPF1 promotes
downstream steps in the NMD pathway beyond factor
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Figure 5 | Phosphorylation-dependent enhanced association of UPF1 with SMG5-7 when downstream NMD factors are limiting. (a) Western blots
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recruitment. For example, in addition to stimulating initiating
events in mRNA degradation via endonucleolytic cleavage,
decapping or deadenylation, UPF1 phosphorylation could also
promote the downstream exonucleolytic degradation of the
mRNA body carried out by general exonucleases. Consistent
with this, depletion of the general 50-to-30 exonuclease XRN1,
required for degrading endonucleolytically cleaved as well as
decapped decay intermediates, induced an increase in UPF1
phosphorylation (Figs 1 and 2) and in phosphorylation-
dependent UPF1 association with NMD factors (Fig. 5).
The importance of UPF1 hyperphosphorylation is likely
conserved in eukaryotes given the conservation of UPF1
hyperphosphorylation and of UPF1 [S/T]Q motifs in
metazoans13,19,28 (Supplementary Fig. 1a). Even in S. cerevisiae
where no SMG1 homologue has been identified, multiple UPF1
phosphorylation sites have recently been described27. An
important question for future study is whether a hierarchy
exists between UPF1 phosphorylation sites. For example, the rate
and/or order of phosphorylation could differ between individual
sites, and the ability of individual sites to recruit and/or activate
individual downstream factors could vary. Consistent with this
idea, some [S/T]Q motifs appear to be more important than
others for UPF1 activity (Figs 4 and 6). Moreover, an interesting
question is how the rapid phosphorylation-dependent buffering
of the NMD pathway uncovered in this study is integrated with
the longer-term autoregulatory mechanism that was recently
revealed, whereby central factors in the NMD pathway are
upregulated when NMD is limiting52,53. In addition to promoting
efficient mRNA degradation, the UPF1 hyperphosphorylation
mechanism could also serve a function as a checkpoint to
ensure that UPF1 is correctly associated with a target mRNA
before activation of degradation, thereby preventing spurious
degradation of non-target mRNAs with which UPF1 associates
transiently24. However, it seems unlikely that a specific
phosphorylation threshold exists upon which the NMD
pathway is activated, given that the extent of UPF1
phosphorylation varies with the severity of the impairment of
the NMD pathway (Figs 1 and 2, and Supplementary Fig. 1b), and
that the number of UPF1 phosphorylation sites becomes
increasingly important for NMD as downstream factors are
rendered limiting (Fig. 6).
Reversible post-translational modifications are common in
regulatory proteins involved in gene expression, but while their
importance in chromatin regulation has long been acknowledged,
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Figure 6 | UPF1 hyperphosphorylation compensates for SMG5 and SMG7 depletion. (a) Northern blots showing the decay of b39 mRNA in HeLa
Tet-Off cells depleted for endogenous UPF1 and expressing the indicated exogenous variants of UPF1. In addition, cells were treated with siRNAs targeting
SMG5 or SMG7, or as a control, Firefly Luciferase (LUC). Numbers above the panels refer to minutes after tetracycline-mediated transcriptional shutoff of
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their role in mRNA regulation remains poorly understood54.
Our observations reveal a role for hyperphosphorylation of an
RNA-binding protein as a mechanism for its associated mRNP to
increasingly activate mRNA decay over time. Repetitive
phosphorylation events are common features of central factors
in gene expression. For example, RNA polymerase II contains in
its C-terminal domain a large array of tandemly repeated
heptameric peptides (for example, 52 in humans), each
containing phosphorylation sites for a key set of kinases
important for recruitment of elongation and processing
factors55–61. Similarly, SR proteins, which play critical roles in
pre-mRNA splicing, contain multiple SR repeats that serve as
phosphorylation sites for SR kinases62,63. Thus, the principle of
hyperphosphorylation as a feedback mechanism to increase
affinity for downstream factors in response to stalling might be
applicable also to other processes in gene expression, for example
in the competition between genes for transcription elongation or
pre-mRNA processing factors or between pre-mRNAs for the
splicing machinery.
Methods
Cell cultures. In all experiments, HeLa tet-off (Clontech), RAW 264.7 (ATCC)
and NIH 3T3 tet-off (Clontech) cells were grown in DMEM (Gibco) with 10%
heat-inactivated fetal bovine serum (FBS, Gibco). When indicated, RAW 264.7 cells
were treated with 100 ngml 1 lipopolysaccharide (LPS; Sigma-Aldrich, L6529).
NIH 3T3 tet-off cells were synchronized in G0 by growing cells for 48 h in DMEM
with 0.2% heat-inactivated FBS, followed by replacement of media with DMEM
containing 20% heat-inactivated FBS (Gibco).
Plasmid constructs and siRNA. pcMyc-UPF1 [S/T]Q to AQ plasmids,
pcMyc-UPF1 G495R, pcMyc-UPF1 G497E and pcMyc-UPF1-C126S were
generated from a pcMyc-UPF1 construct based on pcDNA3 containing full-length
Upf1 (amino acids 1–1,118) with an N-terminal Myc-tag by using the quick
change site-directed mutagenesis method (Stratagene). pcFlag-CAF1B DDAA,
pcFlag-DCP2 E148Q, pcDNA-myc-UPF1 DE636/637AA and pcDNA-myc-UPF1
K498A have been previously described36,64,65. pPC-b39 and pcbWT-UAC-GAP
used in pulse-chase experiments have been described earlier66. The following
siRNAs were used in this study (only sense strand is listed): HEDLS siRNA;
50-GAGUUAAAGAUGUGGUGUA-30; LUC siRNA:50-CGUACGCGGAAUACU
UCGA-30 ; PNRC2 siRNA: 50-UUGGAAUUCUAGCUUAUCA-30 (ref. 15); SMG5
siRNA: 50-GCCAGAAAGAGGUGGGAAA-30 (ref. 14); SMG6 siRNA: 50-GCUGC
AGGUUACUUACAAG-30 (ref. 16); SMG7 siRNA: 50-GCAAGAAACAUCUGUG
AUA-30 (ref. 14); UPF1 siRNA: 50-CCAAGAUGCAGUUCCGCUCCA-30 (ref. 67);
XRN1 siRNA: 50-AGAUGAACUUACCGUAGAA-30 (ref. 16); ZFP36 siRNA:
50-GAAUCCUGGUGCUCAAAUU-30 ; ZFP36L1 siRNA: 50-CCACAACUCAAU
AUGAAAA-30 ; ZFP36L2 siRNA: 50-GUAACAAGAUGCUCAACUA-30 .
Immunoprecipitation assays. For experiments involving siRNA-mediated
depletions, cells were transfected with 20 nM siRNAs using siLentFect (Bio-Rad)
according to manufacturer’s recommendations. Forty-eight hours after the first
siRNA transfection, cells were transfected a second time using the same conditions.
Twenty-four hours later, cells were collected in 1ml of PBS solution (8 g l 1 NaCl,
0.2 g l 1 KCl, 1.44 g l 1 Na2HPO4, 0.24 g l 1 KH2PO4, pH 7.4). In UPF1/SMG6
co-immunoprecipitation assays, 200 ng of pcDNA-myc-UPF1 or pcMyc-UPF1
[S/T]Q mutants and 500 ng of pcDNA-Flag-SMG6 or pcFlag were transfected
using TransIT HeLa Monster reagent according to the manufacturer’s protocol
(Mirus). In experiments involving expression of dominant negative proteins,
200 ng of pcMyc-UPF1-wt, 0.5 mg of pcFlag-CAF1B DDAA, 0.5 mg of pcFlag-DCP2
E148Q and 0.5 mg of empty pcFlag plasmid were transfected using TransIT HeLa
Monster reagent according to the manufacturer’s protocol (Mirus). Forty-eight
hours after transfection, cells were harvested in 1ml PBS. For measuring
phosphorylation of UPF1 ATPase mutants, 200 ng of pcMyc-UPF1-wt or 200 ng of
pcMyc-UPF1 mutants (DE636/637AA, K498A, G495R and G497E) were trans-
fected with 0.8 mg of empty pcFlag plasmid using TransIT HeLa Monster reagent
according to the manufacturer’s protocol. Forty-eight hours after transfection, cells
were collected in 1ml PBS by scraping. Cells collected in PBS were then pelleted
and lysed in 400 ml of hypotonic gentle lysis buffer (10mM Tris-HCl pH 7.5,
10mM NaCl, 2mM EDTA, 0.5% Triton X-100, 0.5mM PMSF, 2mgml 1
leupeptin, 2mgml 1 aprotinin and 1 PhosphataseArrest I phosphatase
inhibitor cocktail (GBiosciences)) for 5min on ice. NaCl concentration was
brought to 150mM and, in co-IP experiments in Fig. 5, RNase A was added at
125 mgml 1. Lysates were incubated for 4 h with 50 ml of protein A sepharose
CL-4B beads (GE Healthcare Life Sciences) conjugated to 2.5 ml of rabbit polyclonal
anti-UPF1 antibody68 or 2.5 ml of mouse monoclonal anti-Myc (Cell Signaling,
clone 9B11). Beads were then washed seven times with NET2 (50mM Tris-HCl pH
7.5, 150mM NaCl and 0.05% Triton X-100) and resuspended in 30 ml of 2X SDS
loading buffer (100mM Tris-HCl pH 6.8, 4% SDS, 12% b-mercaptoethanol, 20%
glycerol and 0.1% bromophenol blue). Immunoprecipitates were separated by
SDS–PAGE followed by western blotting.
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In vitro kinase assays. Bacterially expressed and purified UPF1-HD-SQ69 was
incubated with 150 ng of recombinant ATM (Millipore 14-933), 10 mM ATP
(þ 20 mCi g32P-ATP in assays shown in Supplementary Fig. 5b) in 1 kinase
buffer (10mM HEPES pH 7.5, 50mM NaCl, 10mM MgAc, 10mM MnCl2, 20mM
b-glycerophosphate and 1mM DTT) 30min at 30 C. In vitro kinase reactions
were then analysed by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis or used in pull-down assays.
In vitro pull-down assays. Five microgram of pSG5-FLAG GFP (generously
donated by Dr Samuel Buchsbaum) or 5 mg of pcDNA-FLAG-SMG5 and 5mg of
pcDNA-FLAG-SMG7 or 5mg of pcDNA-FLAG-SMG6 and 10 nM UPF1 siRNA
were transfected in 10 cm dishes using jetPRIME (Polyplus) according to the
manufacturer’s protocol. Forty-eight hours later, cells were collected in PBS and
lysed in 800ml of hypotonic gentle lysis buffer (10mM Tris-HCl pH 7.5, 10mM
NaCl, 2mM EDTA, 0.5% Triton X-100, 1 protease inhibitor cocktail (cOmplete
Tablets EDTA-free, Roche) for 5min on ice. NaCl concentration was brought to
150mM and RNase A was added at 125mgml 1. Lysates were incubated for 2 h
with 100 ml of anti-FLAG M2 affinity gel (Sigma-Aldrich). Beads were then washed
seven times with NET2 (50mM Tris-HCl pH 7.5, 150mM NaCl and 0.05% Triton
X-100) and resuspended in 400ml of NET2 containing 1 protease inhibitor
cocktail (cOmplete Tablets EDTA-free, Roche), 20mM b-glycerophosphate and
UPF1-HD-SQ in vitro kinase reactions. After 2 h incubation at 4 C, beads were
washed five times in NET2 and resuspended in 30 ml of 2 SDS loading buffer
(100mM Tris-HCl pH 6.8, 4% SDS, 12% b-mercaptoethanol, 20% glycerol and
0.1% bromophenol blue). Immunoprecipitates were separated by sSDS–PAGE
followed by western blotting.
Antibodies. Western blotting were performed using the following antibodies:
rabbit polyclonal anti-Myc (Sigma-Aldrich, C3956; 1:1,000), rabbit polyclonal
anti-FLAG (Sigma-Aldrich, F7425; 1:1,000), rabbit polyclonal anti-ACTIN (Cell
Signaling, 4967S; 1:1,000), mouse monoclonal anti-Myc (Cell Signaling, 9B11;
1:1,000), rabbit polyclonal anti-CBP80 (generously provided by E. Izaurralde;
1:1,000), rabbit polyclonal anti-SMG5 (36; 1:1,000), rabbit polyclonal anti-SMG7
(36; 1:1,000), rabbit polyclonal anti-SMG6 (Abcam ab87539; 1:1,000), rabbit
polyclonal anti-ZFP36 N terminus (Sigma-Aldrich, T5327; 1:500), rabbit
polyclonal anti-ZFP36L1 (Cell Signaling, 2119S, 1:1,000), mouse monoclonal
anti-ZFP36L2 (Santa Cruz Technologies, sc-365908, 1:1,000), mouse monoclonal
anti-HuR (Santa Cruz Technologies, sc-5261; 1:20,000), rabbit polyclonal
anti-cFOS (Santa Cruz Technologies, sc-52; 1:1,000), rabbit polyclonal anti-SMG1
(Abcam, ab30916; 1:1,000), rabbit polyclonal anti-SIN3A (Millipore, 06–913;
1:1,000), rabbit monoclonal anti-GAPDH (Cell Signaling, 14C10; 1:1,000), rabbit
polyclonal anti-XRN1 (ref. 44; 1:500), rabbit polyclonal anti-DCP1A (ref. 44;
1:1,000), rabbit polyclonal anti-UPF1 (ref. 68; 1:1,000), rabbit polyclonal anti-UPF2
(ref. 68; 1:1,000) and rabbit polyclonal anti-HEDLS (ref. 70; 1:1,000). UPF1
phosphorylation measurements were performed by incubating blots
simultaneously with mouse polyclonal anti-UPF1 (ref. 68; 1:1,000) and rabbit
polyclonal anti-Phospho-(Ser/Thr) ATM/ATR Substrate (Cell Signaling, 2851;
1:500) or rabbit polyclonal anti-Phospho-S1127-UPF1 (Millipore, 07–1016;
1:1000). Western blots quantifications were performed either by using Cy3 or
Alexa488 conjugated secondary antibodies or by using horseradish peroxidase-
coupled secondary antibodies in combination with ECL plus western blot substrate
(Thermo Scientific). Blots were then visualized using a PhosphorImager (Typhoon
Trio; Amersham Biosciences). Quantifications were performed using ImageQuant
TL 1D software. UPF1 phosphorylation levels were determined by normalizing the
anti-Phospho-(Ser/Thr) ATM/ATR Substrate signal to the anti-UPF1 signal.
P values were calculated by performing paired two-tailed Student’s t-test.
Two-dimensional gel electrophoresis. Cells were either transfected with 20 nM
siRNAs targeting Firefly Luciferase, SMG6 or XRN1 or with 1 mg of pcMyc-UPF1-
wt or pcMyc-UPF1 DE636/637AA as described in the immunoprecipitation section
above. Cells were then collected in 5ml of PBS, pelleted and lysed 10min on ice in
150ml hypotonic gentle lysis buffer (see above) with or without 1 Phosphata-
seArrest I phosphatase inhibitor cocktail (G Biosciences). Cleared lysates were
incubated 2 hours at 30 C with or without 2,000 units of Lambda Protein
Phosphatase according to manufacturer’s protocol (New England Biolabs). Samples
were then incubated in a total of 1ml of 2D sample buffer (2% CHAPS, 100mM
iodoacetamide, 0.002% bromophenol blue, 8M urea, 50mM dithiothreitol) for
10min at room temperature. 2M thiourea was added to cells for 10min and
samples were deionized 1 h with 50mg of AG 501-X8-(D) beads (Bio-Rad). 200 ml
of samples were complemented with 1 ampholytes (Bio-Rad) and separated
in ZOOM strip pH 4–7 strips according to manufacturer’s protocol (Life
Technologies). Strips were then equilibrated for 10min at room temperature in
equilibration buffer 1 (0.375M Tris-HCl pH 8.8, 6M urea, 2% sodium dodecyl
sulfate, 20% glycerol, 2% dithiothreitol) and 10min at room temperature in
equilibration buffer 2 (0.375M Tris-HCl pH 8.8, 6M urea, 2% SDS, 20% glycerol
and 135mM iodoacatamide). Second-dimension electrophoresis was performed in
10% SDS–polyacrylamide gels. Western blots quantifications were performed by
using horseradish peroxidase-coupled secondary antibodies in combination with
ECL plus western blot substrate (Thermo Scientific). Blots were then visualized
using a PhosphorImager (Typhoon Trio; Amersham Biosciences). Quantifications
were performed using ImageQuant TL 1D software. Each pixel was attributed an x
value corresponding to pixel positions along the first-dimension electrophoresis
(pixel position). The pixel intensity for each value of x was normalized by the sum
of all pixel intensities.
Pulse-chase mRNA decay assays. HeLa Tet-Off cells were grown in DMEM
(Gibco) supplemented with 10% heat-inactivated FBS (Gibco) and 50 ngml 1 of
tetracycline (Sigma-Aldrich). For each well of 12-well plates, cells were transfected
with 20 nM siRNA targeting UPF1, and with 20 nM siRNAs targeting luciferase,
SMG5 or SMG7 as indicated, using siLentFect (Bio-Rad) according to
manufacturer’s recommendations. Twenty-four hours after siRNA transfection,
cells were transfected using TransIT HeLa Monster reagent (Mirus) according
to the manufacturer’s protocol, with 0.8 mg of tetracycline-inducible plasmid pPC-
b39, 40 ng of internal control pcbWT-UAC-GAP44 and 100 ng of pcMyc-UPF1-wt,
pcMyc-UPF1 mutants or empty pcDNA-Myc plasmids. Twenty-four hours after
plasmid transfection, cells were transfected a second time with 20 nM siRNA
targeting UPF1 using siLentFect (Bio-Rad). Twenty-four hours later, transcription
was pulsed by washing cells with PBS and adding DMEM with 10% FBS without
tetracycline. Six hours after removal of tetracycline, 1 mgml 1 of tetracycline was
added to repress transcription. Starting 30min later (defined as time 0), cells in
individual wells were collected in 500ml Trizol (Ambion) at time points indicated
in individual experiments and total RNA isolation was performed according to the
manufacturer’s protocol. RNA samples were analysed by electrophoresis (1.2%
agarose, 6% formaldehyde and 0.02M 3-(N-morpholino)propanesulfonic acid)
followed by transfer on Zeta-Probe nylon membrane (Bio-Rad) in 10 SSC (1.5M
NaCl, 0.15M sodium citrate, pH 7)68. Blots were incubated overnight at 60 C in
hybridization buffer (50% deionized formamide, 2 SSC, 0.5% SDS, 25mM
sodium phosphate buffer pH 6.5, 3mg total yeast RNA and 5 Denhardt’s
reagent) containing 32P-aUTP-labelled b-globin antisense RNA probe, washed
four times with wash buffer (0.1 SSC and 0.1% SDS) and then visualized and
quantified using a PhosphorImager (Typhoon Trio; Amersham Biosciences) and
ImageQuant TL 1D software. P values were calculated by performing paired
two-tailed Student’s t-test.
qRT-PCR. Cells transfected with 20 nM siRNA targeting either LUC or
PNRC2 were collected in 500 ml of TRIzol (Life Technologies) and RNA was
isolated according to the manufacturer’s protocol. 1 mg of total RNA was reverse-
transcribed with 100 ng of eight nucleotide random primers using SuperScript III
Reverse Transcriptase (Life Technologies) as recommended by the manufacturer’s
protocols. PCRs were performed on one one-hundredth of the reverse transcription
(RT) reaction using Fast SYBER Green Master Mix (Life Technologies) according
to manufacturer’s recommendations and the Applied Biosystems StepOnePlus
Real-Time PCR System technology. Primers used for PCR: GAPDH: forward,
50-ATTTGGTCGTATTGGGCGCCTG-30 ; reverse, 50-AGCCTTGACGGTGCCAT
GGAATTT-30 ; PNRC2: forward, 50-AGATGGGTGGTGGAGAGAGG-30 ; reverse,
50-TTGCATGGCCTGCCAGGCAG-30 . Each measurement was performed in
duplicate to calculate the average Ct (Threshold Cycle) value. For each set of
primers and each PCR assay, a 10-fold standard dilution was performed to
calculate the PCR efficiency (E). When E value ranged between 1.8 and 2.1, mRNA
levels were determined using average Ct value and E. PNRC2 mRNA levels were
normalized to GAPDH mRNA levels. P values were calculated using a two-tailed
paired Student’s t-test.
Blots have been cropped for presentation purposes. Full-length versions are
available in Supplementary Fig. 7.
Data availability. The authors declare that all other relevant data supporting the
findings of this study are available on request.
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